Loading...
Results from the Women’s Health Initiative and other clinical trials have shown that women using hormone therapy have increased risk for venous thromboembolism (VTE), but only one oral formulation of estrogens and progestin was tested. To determine risks associated with different HT regimens, researchers in France, where hormone-prescribing practices are more diverse than in the U.S., compared 271 postmenopausal women hospitalized for a first-documented episode of idiopathic VTE and 610 controls hospitalized for reasons unrelated to estrogen use.
Women with VTE were on average 1 year older at the time of menopause than controls and were significantly more likely to have higher BMI, varicose veins, and family history of VTE. Overall, women ta…